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Background: Hyperprolactinemia is a common consequence of treatment with 
antipsychotics. It is usually defined by a sustained prolactin level above the laboratory 
upper level of normal in conditions other than that where physiologic hyperprolactinemia 
is expected. Normal prolactin levels vary significantly among different laboratories and 
studies. Several studies indicate that olanzapine does not significantly affect serum 
prolactin levels in the long term, although this statement has been challenged.
Aims: Our aim is to report two olanzapine-induced hyperprolactinemia cases observed 
in psychiatric consultations.
Methods: Medical records of the patients who developed this clinical situation observed 
in psychiatric consultations in the Psychiatry Department of the Prof. Dr. Fernando 
Fonseca Hospital during the year of 2017 were analyzed, complemented with a non-
systematic review of the literature.
Results: The case reports consider two women who developed prolactin-related 
symptoms after the initiation of olanzapine. No baseline prolactinemia was obtained, and 
prolactin serum levels were only evaluated after prolactin-related symptoms developed: 
at the time of its measurement, both patients had been taking olanzapine for more 
than 24 weeks. Hyperprolactinemia was found to be present in Case 2, whereas Case 
1 (a 49-year-old woman) had “normal” serum prolactin levels for premenopausal and 
prolactin levels slightly above the maximum levels for postmenopausal women. Both 
patients underwent similar pharmacological adjustments, which comprised switches 
from olanzapine to aripiprazole. After all pharmacological changes, prolactin serum levels 
decreased to normal range values and prolactin-related symptoms disappeared.
Discussion/Conclusions: Laboratorial and literature prolactinemia values variability 
and discrepancies may make the management of borderline hyperprolactinemia clinical 
situations difficult. Baseline prolactin levels should have been obtained, as they help in the 
management of patients who develop neuroleptic-induced hyperprolactinemia. Prolactin-
related symptoms can occur with borderline or normal standardized prolactinemia values. 
Olanzapine-induced hyperprolactinemia is a rare but possible event. Aripiprazole was 
used as a suitable alternative for olanzapine-induced hyperprolactinemia.
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INTRODUCTION
Hyperprolactinemia is a common (Yasui-Furukori et al., 2010; 
Montejo et al., 2016; Montejo et al., 2017) and underappreciated 
consequence of the treatment with antipsychotic drugs 
(Montejo et al., 2016; Montejo et al., 2017). It is usually defined 
by a sustained prolactin level above the laboratory upper level 
of normal in conditions other than those where physiologic 
hyperprolactinemia is expected (e.g., pregnancy and lactation) 
(Peuskens et al., 2014; Montejo et al., 2017). Prolactin is a 
polypeptide hormone that is mainly synthesized and secreted 
from lactotroph cells of the anterior lobe of the pituitary gland. 
Normal prolactin levels range at 10–20 ng/ml for men and 
10–25 ng/ml for women, although there is significant variability 
among different laboratories and studies (Peuskens et al., 2014). 
Furthermore, there are important interindividual differences 
(e.g., gender, age, stress, nutrition, and exercise) (Peuskens et al., 
2014; Yang et al., 2018) and pronounced circadian variations 
(Peuskens et al., 2014). Hyperprolactinemia can be divided 
according to its severity: mild (50 ng/ml), moderate (51–75 ng/ml), 
and severe (>100 ng/ml) (Montejo et al., 2016).
In women, hyperprolactinemia can cause amenorrhea, 
galactorrhea, cessation of normal cyclic ovarian function, and 
hirsutism. In men, it can cause gynecomastia, impotence, loss of 
libido, and hypospermatogenesis. Long-term hypogonadism due to 
hyperprolactinemia has also been associated with low bone density, 
osteoporosis, hip fracture (Yasui-Furukori et al., 2010; Pérez-
Iglesias et al., 2012; Montejo et al., 2016), prolactinoma (Montejo 
et al., 2017), and increased cardiovascular risk (Montejo et al., 2016; 
Montejo et al., 2017). Women are considered to be more susceptible 
to be affected by antipsychotic-induced hyperprolactinemia; in 
spite of that, there is little literature reporting the trajectory of 
olanzapine-induced hyperprolactinemia in females (Yang et al., 
2018). Preclinical animal models indicate that prolonged high levels 
of prolactin may predispose to breast cancer (Pérez-Iglesias et al., 
2012); what is more, recent clinical studies have strengthened such 
association. The symptoms that accompany prolactin elevation 
not only are unpleasant but also contribute to increased stigma 
(e.g., gynecomastia in males), jeopardizing their health and their 
treatment adherence (Montejo et al., 2016).
Antipsychotic drugs have differences in their propensity to cause 
hyperprolactinemia. Several mechanisms have been proposed 
to explain these variances (Pérez-Iglesias et al., 2012; Montejo 
et al., 2016; Montejo et al., 2017): D2 receptor-binding affinity 
(the stronger the dopamine blockade, the higher the prolactin 
elevation) (Pérez-Iglesias et al., 2012; Peuskens et al., 2014; Montejo 
et al., 2016; Montejo et al., 2017), differential penetrability across 
the blood–brain barrier (Pérez-Iglesias et al., 2012; Montejo et al., 
2016; Montejo et al., 2017), and central mechanisms modulated by 
monoamines other than dopamine (Pérez-Iglesias et al., 2012).
Although first-generation antipsychotics are associated with 
pronounced elevations of prolactin levels (Pérez-Iglesias et al., 
2012; Montejo et al., 2016; Montejo et al., 2017), the highest rates of 
hyperprolactinemia have been reported with sulpiride (Peuskens et 
al., 2014), amisulpride, risperidone (Peuskens et al., 2014; Montejo 
et al., 2016; Montejo et al., 2017), and paliperidone (Montejo et al., 
2016; Montejo et al., 2017). These rates can be as high as 80–90% and 
are consistently greater than those found with other neuroleptics 
(Peuskens et al., 2014). Other second-generation agents are less 
likely to generate sustained hyperprolactinemia (Yasui-Furukori 
et al., 2010; Montejo et al., 2016; Montejo et al., 2017). While 
some authors argue that prolactin response to antipsychotic 
treatments weakens over time (Yasui-Furukori et al., 2010), 
others report that serum prolactin levels tend to remain elevated 
during the length of neuroleptic treatment (Montejo et al., 2017). 
A Multidisciplinary Consensus Group of Experts has proposed a 
routine prolactin level measurement to all antipsychotic-treated 
patients, at baseline and at 3-month time (Montejo et al., 2016). 
Olanzapine, an antipsychotic with an intermediary D2 receptor 
binding affinity, induces a moderate elevation of prolactin levels 
(Peuskens et al., 2014). This elevation is regarded as transient and 
mild compared with that induced by other antipsychotics, such 
as risperidone (Yasui-Furukori et al., 2010; Montejo et al., 2016), 
with studies pointing that olanzapine does not significantly affect 
serum prolactin levels in the long term (Pérez-Iglesias et al., 2012; 
Montejo et al., 2016). There have been inconsistent results regarding 
the relationship between serum prolactin levels and doses/plasma 
concentrations of olanzapine (Peuskens et al., 2014; Takeuchi et al., 
2014), although most studies have demonstrated a dose-dependent 
effect of oral olanzapine on the plasma prolactin level of patients with 
schizophrenia, with higher doses linked to higher prolactin levels 
(Peuskens et al., 2014; Takeuchi et al., 2014; Yang et al., 2018). All 
things considered, prolactin elevation induced by olanzapine remains 
an unclear matter (Yang et al., 2018). Some D2 receptor and 5-HT2A 
receptor gene polymorphisms have been involved in prolactin levels 
after administration of olanzapine (Peuskens et al., 2014); DRD2 
and ANKK1 polymorphisms have been associated with prolactin 
increase in olanzapine-treated women (Houston et al., 2011).
METHODS
We present two case reports of patients observed in psychiatric 
consultations in the Psychiatry Department of the Prof. Dr. Fernando 
Fonseca Hospital during the year of 2017. The case description 
is done through clinical record analysis. Informed consent was 
obtained from the participants for the publication of this case report.
A review of the literature considering psychopharmacy-induced 
hyperprolactinemia and its relationship with olanzapine was also 
performed: PubMed/MEDLINE database search of scientific articles 
[MeSH (Medical Subject Headings) terms “hyperprolactinemia,” 
“olanzapine,” “prolactin,” “olanzapine interactions,” and “fluoxetine”; 
written in English and Spanish; from the year 1999 to 2018] and the 
use of psychopharmacology textbooks.
CASE PRESENTATION
Two cases of olanzapine-induced hyperprolactinemia are presented, 
whose sociodemographic and clinical characteristics can be 
found in Tables 1 and 2.
Both patients developed prolactin-related symptoms after the 
initiation of olanzapine. These patients complained about the 
symptoms at their psychiatric consultations, referring that they 
were significantly disturbing their quality of life. Prolactinemia 
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levels were only obtained after these complaints, as there were 
no asymptomatic prolactin serum levels. At the time when 
prolactinemia levels were obtained, both patients had been 
taking olanzapine for more than 24 weeks.
Patient 1 required one pharmacological adjustment (from oral 
olanzapine 5 mg/day to oral aripiprazole 20 mg/day), allowing 
prolactin-related symptoms to disappear and prolactin serum 
levels to diminish while maintaining psychiatric stability.
Patient 2, on the other hand, showed a symptomatic recrudescence 
from her psychiatric condition after the psychopharmacological 
modification (oral olanzapine 20 mg/day to oral aripiprazole 20 mg/
day), with the resurgence of autoreferential delusion and olfactory 
hallucinations. Such clinical decompensation demanded further 
pharmacological changes, with the initiation of an injectable 
formulation of aripiprazole (400 mg, every 4 weeks) and gradual 
stoppage of oral aripiprazole (20 mg per day). This second adjustment 
allowed for the remission of psychiatric symptoms and simultaneous 
achievement of psychiatric stability. After all pharmacological 
changes, prolactin serum levels decreased to normal range values 
and prolactin-related symptoms vanished.
DISCUSSION
The reference prolactinemia levels available in scientific literature 
did not match with the laboratory values from the hospital where 
these patients were followed up—a discrepancy that may prove 
problematic when managing borderline hyperprolactinemia 
clinical situations. Nevertheless, it is important to bear in 
mind that these “normal” range levels have been found to be 
significantly variable among different laboratories and studies 
(Peuskens et al., 2014).
In Case 1, there was a prolactin increase with only 5 mg of 
olanzapine per day. Being aware that the increases in prolactin 
serum levels induced by olanzapine are uncommon and dose 
related, one might think that the reason behind it would be related 
with its interaction with fluoxetine. However, it is known that the 
changes in olanzapine pharmacokinetics from its coadministration 
with fluoxetine are clinically insignificant (Callaghan et al., 
1999). What is more, even though there were prolactin-related 
symptoms (which disappeared after prolactin serum levels fell), 
the prolactinemia levels in this patient were considered “normal” 
for premenopausal and slightly above the maximum levels for 
postmenopausal women. Taking into account her age (49 years), 
her prolactin levels, and her prolactin-related symptom evolution, 
a possible explanation is that this patient was perimenopausal. 
Otherwise, we may just be sitting in front of a patient with lower 
normal-range values for prolactinemia when compared with 
those of general population; or it may just be the reflection of the 
laboratorial value variability.
The clinical aggravation in Case 2 was possibly related with the 
switch from 20 mg of olanzapine to 20 mg of aripiprazole. According to 
the literature, 20 mg of olanzapine is equivalent to 30 mg of aripiprazole 
(Taylor et al., 2018). Therefore, this psychopharmacological change 
leads to a lower antipsychotic dosage, a probable cause of symptom 
worsening. After a further dosage adjustment (oral aripiprazole 20 
mg/day to injectable aripiprazole 400 mg every 4 weeks), the patient 
became psychiatrically asymptomatic.
Another possible cause for Case 2 relapse may have been due 
to a switch being done between a dopamine receptor antagonist 
(olanzapine) and a dopamine receptor partial agonist (aripiprazole), 
together with the fact that aripiprazole strongly binds to dopamine 
TABLE 1 | Patients’ sociodemographic and basic clinical data.
Case 1 Case 2
Age (in years) 49 29
Gender Female Female
Psychiatric diagnosis 
(ICD-10)
Bipolar affective disorder 
(F31)
Delusional disorder 
(F22.0)
Somatic comorbidities None None
Tobacco smoking No No
TABLE 2 | Prolactin-related clinical data [laboratorial prolactinemia dose ranges (ng/ml): (6.0–29.9) for pre-menopause and (1.8–20.3) for post-menopause].
Case 1 Case 2
Baseline prolactin-related symptoms Galactorrhea and breast pain Galactorrhea, breast tension, and amenorrhea
Baseline medication Fluoxetine 20 mg/day
Olanzapine 5 mg/day
Olanzapine 20 mg/day
Aripiprazole 2.5 mg/day
Pharmacological changes Switch olanzapine–aripiprazole through 
partial overlap (switch duration: 1 month)
Switch olanzapine 20 mg/day to aripiprazole 
20 mg/day through partial overlap (switch duration: 
2 months)
Psychiatric disorder relapse No Yes
Second pharmacological modification due to relapse N/A Initiation of aripiprazole injectable formulation 400 mg 
every 4 weeks. Gradual stoppage of aripiprazole oral 
20 mg/day
Medication after all pharmacological adjustments Fluoxetine 20 mg/day
Aripiprazole 20 mg/day
Aripiprazole injectable formulation 400 mg every 
4 weeks
Prolactinemia before pharmacological adjustments (ng/ml) 20.73 50
Prolactinemia after pharmacological all adjustments (ng/ml) 7.27 8.51
Prolactin-related symptoms after all pharmacological 
adjustments
Asymptomatic Asymptomatic
Psychiatric disorder after all pharmacological adjustments Stable Stable
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receptors, displacing almost every other antipsychotic and 
stimulating receptors from minimal dopamine activity to about 
30%, which can be acutely distressing and aversive (Bazire, 2014).
Olanzapine-induced prolactin serum level elevation has been 
described as transient, equaling placebo at week 6 (Callaghan et al., 
1999; Montejo et al., 2016). However, both patients were medicated 
with olanzapine for more than 24 weeks, a fact that reinforces their 
clinical atypicality and, consequently, their scientific importance.
Contrary to what is suggested in the literature, there were no 
baseline plasma prolactin levels, as they were only obtained after 
patients complained of prolactin-related symptoms. If these levels 
had been collected, an earlier pharmacological intervention might 
have been possible, perhaps lessening the appearance, duration, or 
disturbance caused by prolactin-related symptoms.
The switch to aripiprazole, as advised in the literature (Montejo 
et al., 2016; Montejo et al., 2017), was a successful approach in 
both patients, not only diminishing serum prolactin values but 
also solving prolactin-related symptoms and maintaining clinical 
stabilization.
CONCLUSION
Literature prolactinemia values do not always correspond with 
laboratory values from clinical practice, a discrepancy that may 
make the management of borderline hyperprolactinemia clinical 
situations difficult. Baseline prolactin level collection may help 
in the management of patients who develop neuroleptic-induced 
hyperprolactinemia. Prolactin-related symptoms can occur 
with borderline or normal standardized prolactinemia values. 
Olanzapine-induced hyperprolactinemia is a rare event, but it is 
not nonexistent. Aripiprazole was used as a suitable alternative 
for olanzapine-induced hyperprolactinemia.
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